

Active substances set

Search phrase: trastuzumab deruxtecan

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Malignant stomach cancer

Trastuzumab deruxtecan	Trastuzumab Deruxtecan as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.	FULL REIMBURSEMENT ESMO

Colon and rectum cancer

Trastuzumab deruxtecan	Other unresectable or metastatic solid tumours Trastuzumab deruxtecan as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumours who have received prior treatment and who have no satisfactory treatment options.	NO REIMBURSEMENT ESMO

Tracheal, bronchus, and lung cancer

Trastuzumab deruxtecan	Trastuzumab Deruxtecan as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.	NO REIMBURSEMENT ESMO

Malignant breast cancer

Trastuzumab deruxtecan	Trastuzumab Deruxtecan as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. Trastuzumab Deruxtecan as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.	REIMBURSEMENT WITH RESTRICTIONS ESMO